CAS: 24356-66-9; (2R,3S,4S,5R)-2-(6-Amino-9H-Purin-9-yl)-5-(Hydroxymethyl)Tetrahydrofuran-3,4-Diol Hydrate

该化合物是一种核素的类似物,具有重要的抗病毒特性,其特点是其纯碱基,adenine,与-D-arabinofurusyl sugar mothis, 相联;该化合物通常以水分形式出现,表明水分子在其晶体结构中的存在;Ara-A展示一种分子配方,反映其核素性质,包括碳,氢,氮和氧原子;其行动机制主要包括抑制病毒复制,使其成为对某些病毒感染进行治疗用途的候选;该化合物在水中可溶解,有利于生物系统中的生物利用;此外,Ara-A还就其对细胞过程的潜在影响进行了研究,包括其在核糖酸代谢中所起的作用;与许多核素类类模拟一样,它可能展示其副作用,在一种重要的化合物中,特别是临床环境化学环境中,需要展示一种重要的化合物.

结构式图片

欧盟法规

C&L通报

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2004242897-A1
    优先权日:2002-07-31
    标题 :Universal support media for synthesis of oligomeric compounds
    发明人:GUZAEV ANDREI P; MANOHARAN MUTHIAH
    摘要:Compounds for the synthesis of oligomeric compounds, particularly oligonucleotides and oligonucleotide mimetics, are provided. In addition, methods for functionalizing a support medium with a first monomeric subunit and methods for the synthesis of oligomeric compounds utilizing the novel compounds bound to support media are provided.

    专利号:WO-2004011474-A1
    优先权日:2002-07-31
    标题:Universal support media for synthesis of oligomeric compounds
    发明人:GUZAEV ANDREI P; MANOHARAN MUTHIAH; RAVIKUMAR VASULINGA T; KUMAR RAJU K
    权利人:ISIS PHARMACEUTICALS INC; GUZAEV ANDREI P; MANOHARAN MUTHIAH; RAVIKUMAR VASULINGA T; KUMAR RAJU K
    摘要:Compounds for the synthesis of oligomeric compounds, particularly oligonucleotide and oligonucleotide mimetics, are provided. In addition, methods for functionalizing a support medium with a first monomeric subunit and methods for the synthesis of oligomeric compounds utilizing the novel compounds bound to support media are provided.

    专利号:US-6653468-B1
    优先权日:2002-07-31
    标 题 :Universal support media for synthesis of oligomeric compounds
    发明人:GUZAEV ANDREI P; MANOHARAN MUTHIAH
    权利人:ISIS PHARMACEUTICALS INC
    摘要:Compounds for the synthesis of oligomeric compounds, particularly oligonucleotides and oligonucleotide mimetics, are provided. In addition, methods for functionalizing a support medium with a first monomeric subunit and methods for the synthesis of oligomeric compounds utilizing the novel compounds bound to support media are provided.

    专利号:US-2020239921-A1
    优先权日:2016-02-03
    标 题 :Chemoenzymatic synthesis of s-nucleosyl amino acids (sna), analogs of s-adenosyl-l-methionine and s-adenosyl-l- homocysteine and uses thereof
    发明人:BURGOS EMMANUEL SEBASTIEN; SHECHTER DAVID
    权利人:ALBERT EINSTEIN COLLEGE MEDICINE
    摘要:Disclosed are methods for chemoenzymatic synthesis of S-Nucleosyl Amino acid probes (SNA), analogs of S-adeno-syl-L-methionine and S-adenosyl-L-homo-cysteine, analogs synthesized by the methods, and uses thereof.

    专利号:US-6818633-B2
    优先权日:2001-06-29
    标题:Antiviral compounds and methods for synthesis and therapy
    发明人:BALZARINI JAN M R; DE CLERCQ ERIK D A; HOLY ANTONIN
    权利人:ACAD OF SCIENCE CZECH REPUBLIC; REGA STICHTING
    摘要:Novel compounds are provided having formula (I)whereR1, R2, R3, R4, Z, X and * are defined herein. Also provided are antiviral methods for use and processes for synthesis of the compounds of formula (I).

    专利号:US-11311505-B2
    优先权日:2017-02-24
    标 题:Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts
    发明人:MARTIN ALAIN
    权利人:MARTIN ALAIN; CELLULAR SCIENCES INC
    摘要:Methods for the treatment of patients with both Chronic Obstructive Pulmonary Disease (COPD) and pulmonary fibrosis, and of patients with idiopathic pulmonary fibrosis without COPD, by stimulating the synthesis of human and animal patient lung and sinus surfactants to increase lung functions, inhibiting fibrosis and reducing coughing and nasal erythema, include the following steps: A) analyzing and diagnosing a patient with a lung ailment selected from the group consisting of i) both COPD and pulmonary fibrosis; and ii) idiopathic pulmonary fibrosis without COPD; and, B) treating the patient to raise the patient's lung functions including FEV1/FVC ratio by contacting mammalian cells with a [therapeutically effective amount of a treatment] composition that includes: a) a pyruvate salt; b) a phosphate; c) a salt of calcium; and d) a salt of magnesium, in an aqueous carrier, containing no more than 2.2 grams of said pyruvate salt per liter.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.3390/ijms12064027
    摘要:Prussia A, Thepchatri P, Snyder JP, Plemper RK. Systematic approaches towards the development of host-directed antiviral therapeutics. Int J Mol Sci. 2011;12(6):4027–52.
    参考文献:10.1111/j.1365-2141.2011.08784.x
    摘要:Garbe E, Andersohn F, Bronder E, Klimpel A, Thomae M, Schrezenmeier H, Hildebrandt M, Späth-Schwalbe E, Grüneisen A, Mayer B, Salama A, Kurtal H. Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br J Haematol. 2011 Sep;154(5):644–53. doi: 10.1111/j.1365-2141.2011.08784.x.
    参考文献:10.1111/j.1600-0609.2011.01680.x
    摘要:Chow KU, Kim SZ, von Neuhoff N, Schlegelberger B, Stilgenbauer S, Wunderle L, Cordes HJ, Bergmann L. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. Eur J Haematol. 2011 Nov;87(5):426–33. doi: 10.1111/j.1600-0609.2011.01680.x.
    参考文献:10.1182/blood-2011-01-329177
    摘要:Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011 Aug 25;118(8):2062–8.
    参考文献:10.1007/s11912-011-0183-y
    摘要:Solis EC. Treatment strategies in patients with core-binding factor acute myeloid leukemia. Curr Oncol Rep. 2011 Oct;13(5):359–60. doi: 10.1007/s11912-011-0183-y.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知